Vitronectin: Possible contribution to the closed-eye external host-defense mechanism

References

• Selinger D S, Selinger R C, Reed W P. Resistance to infection of the external eye; the role of tears. Surv Ophthalmol 1979; 24: 33–38
   PubMed Web of Science ®Google Scholar
• Sack R A, Tan K O, Tan A. Diurnal tear cycle: evidence for a nocturnal inflammatory constitutive tear fluid. Invest Ophthalmol Vis Sci 1992; 33: 626–640
   PubMed Web of Science ®Google Scholar
• Sack R A, Tan K O, Chuck J, Holden B A, Vannas A. Eye closure induces activation of tear plasminogen and complement systems. Invest Ophthalmol Vis Sci 1992; 33(suppl)849
   Google Scholar
• Tan K O, Sack R A, Holden B A. Temporal sequence of changes in tear protein composition following eye closure. Invest Ophthalmol Vis Sci 1993; 34(suppl)1468
   Google Scholar
• Fullard R J, Snyder C. Protein levels in nonstimulated and stimulated tears of normal human subjects. Invest Ophthalmol Vis Sci 1990; 31: 1119–1126
   PubMed Web of Science ®Google Scholar
• van Haeringen N J. Clinical biochemistry of tears. Surv Ophthalmol 1981; 26: 84–96
   PubMed Web of Science ®Google Scholar
• Janssen P T, van Bijsterveld O P. Origin and biosynthesis of human tear fluid proteins. Invest Ophthalmol Vis Sci 1983; 24: 623–630
   PubMed Web of Science ®Google Scholar
• Maurice D M. The dynamics and drainage of tears. Int Ophthalmol Clin 1973; 13: 103–116
   PubMedGoogle Scholar
• Kijlstra A. The role of lactoferrin in the nonspecific immune response on the ocular surface. Regional Immunol 1990–91; 3: 193–197
   Google Scholar
• Kijlstra A. Jeurissen SHM. Modulation of classical C3 convertase of complement by tear lactoferrin. Immunology 1982; 47: 263–270
   PubMed Web of Science ®Google Scholar
• Lass J H, Walter E I, Burris T E, et al. Expression of two molecular forms of the complement decay-accelerating factor in the eye and lacrimal gland. Invest Ophthalmol Vis Sci 1990; 31: 1136–1148
   PubMed Web of Science ®Google Scholar
• Vannas A, Sweeney D F, Holden B A, Sapyska E, Salonen E M, Vaheri A. Plasmin activity with contact lens wear. Curr Eye Res 1992; 11: 243–251
   PubMed Web of Science ®Google Scholar
• Wilson G, O'Leary D J, Holden B A. Cell content of tears following overnight wear of a contact lens. Curr Eye Res 1989; 8: 329–335
   PubMed Web of Science ®Google Scholar
• Tschopp J, Masson D, Schafer S., Peitsch M, Preissner K T. The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and porphin from cytolytic T-cells and inhibits their lytic activities. Biochemistry 1988; 27: 4103–4109
   PubMedGoogle Scholar
• Keijer J, Ehrlich H J, Linders M, Preissner K T, Pannekoek H. Vitronectin governs the interaction between plasminogen activator inhibitor1 and ti-type plasminogen activator. J Biol Chem 1991; 266: 10700–10707
   Google Scholar
• Hermann M, Jaconi M E, Dahlgren C, Waldvogel F A, Sendahl O, Lew D P. Neutrophil bactericidal activity against Staphylococcus aureus adherent to biological surfaces. Surface-bound extracellular matrix proteins activate intracellular killing by oxygen-dependent and -independent mechanisms. J Clin Invest 1990;; 86: 942–951
   Google Scholar
• Parker C J, Frame R N, Elstad M R. Vitronectin (S-protein) augments the functional activity of monocyte receptors for IgG and complement C3b. Blood 1988; 71: 86–93
   Google Scholar
• Kawahira H. Clinical and experimental studies on vitronectin in bacterial pneumonia. J Jap Assoc for Infectious Diseases 1990; 64: 741–751
   Google Scholar
• Kabata T, Ishibashi Y, Honmura S, Akama T, Yatohgo T, Kono I, et al. Effect of vitronectin on the healing of rabbit corneal epithelial damage. Nippon Ganka Gakkai Zasshi 1990; 94: 457–461
   Google Scholar
• Holden B A, Tan K O, Sack R A, Sweeney D F, Wong R, Ho A. Human tear protein: consistency and measurement accuracy. Invest Ophthalmol Vis Sci 1992; 33(suppl)1288
   Google Scholar
• Yatohgo T, Izumi M, Kashiwagi H, Hayashi M. Novel purification of vitronectin from human plasma by heparin affinity chromatography. Cell Structure and Function 1988; 13: 281–292
   PubMed Web of Science ®Google Scholar
• Underwood P A, Steele J G, Dalton B A, Bennett F A. Solid-phase monoclonal antibodies: a novel method of directing the function of biologically active molecules by presenting a specific orientation. J Immunol Meth 1990; 127: 91–101
   PubMedGoogle Scholar
• Boonstra A, van Haeringen N, Kijlstra A. Human tears inhibit the coating of proteins to solid phase surfaces. Curr Eye Res 1985; 4: 1137–1144
   PubMed Web of Science ®Google Scholar
• McLean I W, Nakane P K. Periodate-lysine-paraformaldehyde fixative: a new fixative for immunoelectron microscopy. J Histochem Cytochem 1974; 22: 1077–1083
   PubMed Web of Science ®Google Scholar
• Colon M G, Tomasini B R, Shultz R L, Mosher D F. Plasma vitronectin polymorphism in normal subjects and patients with disseminated intravascular coagulation. Blood 1988; 72: 185–190
   Google Scholar
• Reilly J T, Nash J RG. Vitronectin (serum spreading factor): its localisation in normal and fibrotic ti. J Clin Pathol 1988; 41: 1269–1272
   PubMedGoogle Scholar
• Underwood P A, Bennett F A. A comparison of the cell-adhesive proteins vitronectin and fibronectin. J Cell Sci 1989; 93: 641–649
   PubMed Web of Science ®Google Scholar
• Tomasini B R, Mosher D F. Vitronectin. Prog Hemost Thromb 1991; 10: 269–305
   Google Scholar
• de Boer H C, Preissner K T, Bouma B N, de Groot P G. Binding of vitronectin-thrombin-antithrombin III complex to human endothelial cells is mediated by the heparin binding site of vitronectin. J Biol Chem 1992; 267: 2264–2268
   PubMedGoogle Scholar
• Izumi M, Shimo-Oka T, Morishita N, Ii I, Hayashi M. Identification of the collagen-binding domain of vitronectin using monoclonal antibodies. Cell Structure and Function 1988; 13: 217–225
   Google Scholar
• Chhatwal G S, Preissner K T, Muller-Berghaus G, Blobel H. Specific binding of the human S-protein (vitronectin) to Streptococci, Staphylococcus aureus, and Escherichia coli. Infection and Immunity 1987; 55: 1878–1883
   PubMed Web of Science ®Google Scholar
• Preissner K T, Anders E, Grulich-Henn J, Muller-Berghaus G. Attachment of cultured human endothelial cells is promoted by specific association with S-protein (vitronectin) as well as with the ternary S-protein-thrombin-antithrombin III complex. Blood 1988; 71: 1581–1589
   PubMed Web of Science ®Google Scholar
• Halfter W, Diamantis I, Monard D. Migratory behaviour of cells on embryonic retinal basal lamina. Developmental Biol 1988; 130: 259–275
   PubMedGoogle Scholar
• Savill J, Dransfield I, Hogg N, Haslett C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 1990; 343: 170–173
   PubMed Web of Science ®Google Scholar
• Berta A, Tözsér J, Holly F J. Determination of plasminogen activator activities in normal and pathological human tears. The significance of tear plasminogen activators in the inflammatory and traumatic lesions of the cornea and the conjunctiva. Acta Ophthalmol 1990; 68: 508–514
   PubMedGoogle Scholar
• Neoh S H, Sage M R, Willis R B, Roberts-Thomson P, Bradley J. The in vitro activation of complement by radiologic contrast materials and its inhibition with e-aminocaproic acid. Invest Radiol 1981; 16: 152–158
   Google Scholar
• Till G O. Chemotactic factors. The Complement System, K Rother, G O Till. Springer-Verlag, Berlin 1988; 354–367
   Google Scholar